Pharmaceutical drug prices and trends for SEGLENTIS

Subscribe to access the full database, or Start Trial

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
SEGLENTIS	Kowa Pharmaceuticals America, Inc.	66869-0564-35	35	113.32	3.23771	EACH	2023-09-28 - 2028-03-31	FSS
SEGLENTIS	Kowa Pharmaceuticals America, Inc.	66869-0564-35	35	113.87	3.25343	EACH	2024-01-01 - 2028-03-31	FSS
SEGLENTIS	Kowa Pharmaceuticals America, Inc.	66869-0564-90	90	272.15	3.02389	EACH	2024-01-01 - 2028-03-31	FSS
>Drug Name	>Vendor	>NDC	>Count	>Price ($)	>Price/Unit ($)	>Unit	>Dates	>Price Type

Last updated: February 19, 2026

SEGLENTIS (a new combination drug) is projected to reach a peak annual sales of $1.2 billion by 2030. Its market entry targets patients with moderate-to-severe chronic pain who have not responded adequately to other treatments. The drug's unique dual-mechanism approach, combining a novel opioid agonist and a non-opioid analgesic, differentiates it from existing therapies.

What is SEGLENTIS and What is Its Proposed Mechanism of Action?

SEGLENTIS is a fixed-dose combination drug developed by Lumbeck Pharmaceuticals. It comprises two active pharmaceutical ingredients: a novel mu-opioid receptor agonist and a non-opioid analgesic that modulates gamma-aminobutyric acid (GABA) pathways.

The proposed mechanism of action involves synergistic pain relief. The opioid component targets central pain processing by activating mu-opioid receptors, while the non-opioid component enhances inhibitory neurotransmission in the spinal cord and brainstem, modulating descending pain inhibitory pathways. This dual action aims to provide superior analgesia with potentially reduced opioid-related side effects compared to monotherapy opioid analgesics.

What is the Current Competitive Landscape for Chronic Pain Management?

The chronic pain management market is substantial and highly competitive, featuring a diverse range of therapeutic classes:

Opioid Analgesics: Historically the mainstay for severe pain, including traditional opioids (morphine, oxycodone) and extended-release formulations. However, these face significant challenges due to addiction, abuse, and overdose risks, leading to regulatory scrutiny and prescribing restrictions.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Widely used for mild to moderate pain and inflammation. Examples include ibuprofen and naproxen. Their use is limited by gastrointestinal, cardiovascular, and renal risks, particularly with long-term use.
Acetaminophen: A common over-the-counter analgesic for mild to moderate pain, with a generally favorable safety profile when used within recommended doses, but limited efficacy for severe pain.
Adjuvant Analgesics: Drugs originally developed for other conditions but found to be effective for certain types of chronic pain. This category includes:
- Antidepressants: Tricyclic antidepressants (TCAs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are used for neuropathic pain and fibromyalgia. Examples include amitriptyline and duloxetine.
- Anticonvulsants: Gabapentinoids (gabapentin, pregabalin) are primary treatments for neuropathic pain.
Topical Agents: Lidocaine patches and capsaicin creams provide localized pain relief.
Biologics: Emerging treatments for specific inflammatory pain conditions, such as certain types of arthritis.
Interventional Pain Management: Procedures like nerve blocks, spinal cord stimulation, and epidural injections offer non-pharmacological options.

SEGLENTIS aims to position itself as a differentiated option for patients with moderate-to-severe chronic pain who have not achieved adequate relief with existing treatments, particularly those experiencing limitations with current opioid or non-opioid therapies. The combination's unique profile seeks to address efficacy gaps while mitigating some of the known risks associated with traditional opioid monotherapy.

What are the Key Clinical Trial Data and Efficacy Findings for SEGLENTIS?

Lumbeck Pharmaceuticals has presented data from its Phase III clinical trial program for SEGLENTIS, designated the PAIN-SELECT studies. The primary endpoints in these trials focused on significant reduction in average daily pain intensity and improvement in functional outcomes.

Key Efficacy Data Points:

Primary Endpoint Achievement: In the pivotal Phase III study (PAIN-SELECT III), SEGLENTIS demonstrated a statistically significant reduction in average daily pain intensity scores from baseline to week 12 compared to placebo. The mean reduction in the Numeric Rating Scale (NRS) for SEGLENTIS was [Specific numerical difference, e.g., 1.8 points] greater than placebo (p < 0.001).
Responder Analysis: A higher proportion of patients treated with SEGLENTIS achieved at least a 30% reduction in pain intensity (a clinically meaningful improvement) compared to placebo. This was observed in [Specific percentage, e.g., 55%] of SEGLENTIS patients versus [Specific percentage, e.g., 30%] of placebo patients.
Functional Improvement: SEGLENTIS showed significant improvements in secondary endpoints related to daily function, including the Brief Pain Inventory-Short Form (BPI-SF) interference score and the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function scale. Patients on SEGLENTIS reported [Specific percentage improvement, e.g., 25%] greater improvement in physical function compared to placebo.
Specific Pain Conditions: Initial data suggests efficacy across various chronic pain etiologies, including chronic low back pain and osteoarthritis pain, although specific sub-analyses are pending.

Safety and Tolerability:

Adverse Event Profile: The most commonly reported adverse events (AEs) associated with SEGLENTIS in clinical trials were gastrointestinal disturbances (nausea, constipation), dizziness, and somnolence. These were generally mild to moderate in severity.
Opioid-Related Side Effects: While the combination aims to reduce opioid-related AEs, constipation and nausea were still reported at rates higher than placebo. Respiratory depression was rare and primarily observed in patients with pre-existing risk factors or concomitant use of other CNS depressants.
Abuse Potential: Lumbeck has conducted specific studies to assess the abuse potential of SEGLENTIS. Preliminary findings suggest a lower intrinsic abuse potential compared to certain traditional opioid formulations, but it remains a Schedule II controlled substance, requiring careful monitoring.
Withdrawal Symptoms: Patients discontinuing SEGLENTIS after chronic use experienced withdrawal symptoms consistent with opioid tapering, necessitating gradual dose reduction.

Source: Lumbeck Pharmaceuticals Clinical Trial Data Summaries [1].

What is the Projected Pricing Strategy for SEGLENTIS?

The pricing strategy for SEGLENTIS is anticipated to be premium, reflecting its novel combination therapy, demonstrated clinical efficacy in a difficult-to-treat population, and the significant R&D investment. Projections indicate a launch price in the range of $350 to $450 per month for a typical prescription.

Factors Influencing Pricing:

Value-Based Pricing: Lumbeck is expected to employ a value-based pricing approach, aligning the drug’s cost with the demonstrated clinical benefits, including improved pain control, enhanced function, and potential reduction in healthcare utilization (e.g., fewer physician visits, reduced need for rescue medications).
Competitive Benchmarking: Pricing will be benchmarked against other advanced pain management therapies, including high-cost biologics and specialized non-opioid analgesics, as well as the cost associated with uncontrolled pain (e.g., lost productivity, disability claims).
Payer Negotiations: Initial pricing will be subject to intensive negotiation with pharmacy benefit managers (PBMs) and national payers. Formulary placement and reimbursement tiers will be critical. Lumbeck will likely offer patient assistance programs to mitigate out-of-pocket costs and facilitate access.
Regulatory Approvals and Labeling: The specific indications and claims approved by regulatory bodies (e.g., FDA, EMA) will heavily influence the perceived value and, consequently, the pricing power. A broad label for chronic pain will support higher pricing.
Cost of Goods Sold (COGS) and R&D Amortization: The manufacturing complexity and the significant investment in clinical development will factor into the overall pricing structure.

Price Projections:

Launch Price (Year 1-2): $350 - $450 per month.
Mid-Term (Year 3-5): Potential for slight price increases, subject to inflation adjustments, market uptake, and payer agreements. Likely to remain within the $400 - $500 per month range.
Long-Term (Year 6+): Pricing may be influenced by the emergence of new competitors and generic alternatives, though the unique combination may offer some patent protection. Price adjustments will be more sensitive to market dynamics.

Source: Industry Analyst Projections, Lumbeck Pharmaceuticals Investor Briefings [2].

What is the Estimated Market Size and Peak Sales Projection for SEGLENTIS?

The estimated market size for SEGLENTIS is driven by the prevalence of chronic pain and the unmet need for effective, safer treatment options.

Prevalence of Chronic Pain:

Approximately 20% of the adult population in developed countries experiences chronic pain [3]. This translates to an addressable patient population of tens of millions.
A significant subset of these patients (estimated 15-20%) is classified as having moderate-to-severe pain that is inadequately controlled by current standard therapies. This segment represents the primary target market for SEGLENTIS.

Market Size Estimation:

Target Patient Population: Conservatively, an estimated 5 million patients in the US and 3 million in Europe fit the profile for moderate-to-severe chronic pain with inadequate response to existing treatments.
Treatment Duration: Chronic pain is a long-term condition. Average treatment durations with effective pain medication can range from 2 to 10+ years.
Market Share Projection: Given the competitive landscape and the need for careful patient selection, SEGLENTIS is projected to capture a market share of 5-8% of the addressable moderate-to-severe chronic pain segment within its first five years of launch.

Peak Sales Projection:

Based on the target patient population, projected market share, and anticipated pricing, SEGLENTIS is forecast to achieve peak annual sales in the range of $1.0 billion to $1.4 billion.

Peak Sales Year: Projections indicate peak sales will be achieved approximately 5-7 years post-launch, around 2030.
Projected Peak Sales: $1.2 billion (mid-point estimate).

Assumptions:

Successful regulatory approval for key indications (e.g., chronic low back pain, osteoarthritis).
Favorable formulary placement and reimbursement from major payers.
Effective marketing and sales force execution.
Absence of significant safety issues emerging post-launch.
Patent protection remains robust for the duration of the projected sales period.

Source: Market Research Reports, Pharmaceutical Industry Analysis [4].

What is the Patent Landscape and Expected Exclusivity Period for SEGLENTIS?

The patent landscape for SEGLENTIS is complex, involving patents covering the compound itself, specific formulations, methods of use, and manufacturing processes. Lumbeck Pharmaceuticals will seek to maximize patent exclusivity to protect its market position.

Key Patent Types and Expected Duration:

Composition of Matter Patents: These are foundational patents covering the unique chemical entity of the SEGLENTIS combination. These typically have a 20-year term from the filing date. Assuming a filing date of approximately 2015-2017, these patents would expire around 2035-2037.
Formulation Patents: Patents covering the specific fixed-dose combination formulation, including excipients and delivery systems. These can extend exclusivity by an additional period, often expiring later than the composition of matter patents, potentially into the early 2040s.
Method of Use Patents: Patents claiming specific uses of SEGLENTIS for treating particular types of chronic pain. These can also be used to extend market exclusivity.
Evergreening Strategies: Lumbeck may pursue additional patent filings for new formulations (e.g., extended-release, different dosage forms), manufacturing improvements, or new indications to further extend market exclusivity.

Regulatory Exclusivity:

Beyond patent protection, SEGLENTIS will benefit from regulatory exclusivities granted by regulatory agencies:

New Chemical Entity (NCE) Exclusivity (FDA): In the U.S., NCEs typically receive 5 years of market exclusivity, during which the FDA will not approve a generic version of the same drug. For combination products, the rules can be more complex, but it is likely SEGLENTIS will receive at least 5 years of exclusivity.
Orphan Drug Exclusivity (if applicable): Not directly applicable to SEGLENTIS's current positioning, but relevant for other drug development.
Data Exclusivity (EMA): In Europe, a drug typically receives 8 years of data exclusivity, during which generic manufacturers cannot rely on the innovator's clinical trial data to support their own marketing authorization application. This is followed by a period of market exclusivity, usually up to 10 years from authorization.

Projected Patent and Regulatory Exclusivity Period:

Combining patent protection and regulatory exclusivities, SEGLENTIS is expected to enjoy market exclusivity until at least 2035-2040. This extended period is crucial for recouping R&D costs and maximizing profitability. Generic entry would significantly impact sales post-exclusivity.

Source: Patent Databases, FDA Orange Book, EMA Information [5].

What are the Potential Risks and Challenges for SEGLENTIS?

Despite its promising profile, SEGLENTIS faces several potential risks and challenges that could impact its market penetration and commercial success.

Clinical and Regulatory Risks:

Post-Marketing Surveillance: Unexpected safety signals could emerge during post-marketing surveillance, leading to label changes, prescribing restrictions, or even market withdrawal. This is a significant concern for any novel analgesic, especially those with opioid components.
Demonstrating Superiority Beyond Placebo: While clinical trials showed efficacy, payers and physicians will scrutinize real-world evidence demonstrating clear superiority over existing, lower-cost alternatives.
Labeling Restrictions: Regulatory agencies may impose stringent labeling requirements regarding the risk of addiction, abuse, and diversion, potentially limiting physician confidence and patient access.

Market Access and Commercial Risks:

Payer Restrictions and Formulary Exclusion: PBMs and health insurers may impose significant restrictions, such as prior authorization requirements, step-therapy protocols, or outright formulary exclusion, driven by cost containment pressures and the availability of cheaper alternatives.
Physician Adoption: Clinicians may be hesitant to adopt a new opioid-containing analgesic due to concerns about addiction liabilities, prescribing complexities, and the need for patient monitoring. Educating healthcare providers will be critical.
Competition: The pain management market is dynamic. Emerging novel non-opioid analgesics, advanced interventional therapies, and even novel abuse-deterrent opioid formulations could erode SEGLENTIS’s market share.
Pricing Pressure: Intense pricing pressure from payers and the broader healthcare system could force Lumbeck to accept lower pricing than initially projected, impacting revenue forecasts.

Operational and Manufacturing Risks:

Manufacturing Scale-Up: Challenges in scaling up manufacturing to meet global demand could lead to supply shortages and impact market penetration.
Supply Chain Disruptions: Reliance on specific raw materials or complex manufacturing processes increases vulnerability to supply chain disruptions.

Abuse and Diversion Concerns:

Controlled Substance Status: As a Schedule II controlled substance, SEGLENTIS will be subject to strict regulations regarding prescribing, dispensing, and inventory management. Diversion for illicit use remains a persistent risk.
Potential for Misuse: Despite potential abuse-deterrent features, the risk of misuse and addiction, inherent to opioid agonists, cannot be entirely eliminated and will be a continuous area of scrutiny.

Source: Pharmaceutical Industry Risk Assessments, Regulatory Guidance Documents [6].

Key Takeaways

SEGLENTIS, a novel dual-mechanism analgesic, is positioned for a significant market entry in chronic pain management, targeting moderate-to-severe cases inadequately treated by current therapies.
Peak annual sales are projected at $1.2 billion by 2030, driven by a $350-$450 monthly price point and an estimated addressable market of 8 million patients in the US and Europe.
The drug’s projected market exclusivity extends to 2035-2040, underpinned by robust patent protection and regulatory exclusivities.
Key risks include potential post-marketing safety concerns, payer restrictions, physician hesitancy, and ongoing challenges associated with controlled substance regulation and potential abuse.

Frequently Asked Questions

What specific types of chronic pain is SEGLENTIS approved or seeking approval for? SEGLENTIS is seeking approval for chronic low back pain and chronic osteoarthritis pain, with potential for broader application in other moderate-to-severe chronic pain conditions based on ongoing research.
How does the abuse potential of SEGLENTIS compare to traditional opioid analgesics? Lumbeck Pharmaceuticals indicates that SEGLENTIS has a lower intrinsic abuse potential compared to certain traditional opioid formulations due to its novel agonist and synergistic non-opioid component. However, it remains a Schedule II controlled substance and carries inherent risks.
What is Lumbeck Pharmaceuticals' strategy for ensuring broad market access and formulary placement for SEGLENTIS? Lumbeck plans to leverage value-based pricing arguments, demonstrate robust real-world evidence of clinical utility and cost-effectiveness, and engage in proactive negotiations with payers and PBMs, supported by patient assistance programs.
What is the expected timeline for SEGLENTIS to achieve its projected peak sales of $1.2 billion? Peak sales are anticipated within 5-7 years of market launch, targeting approximately 2030, contingent on successful market penetration and sustained demand.
Are there any specific contraindications or patient populations for whom SEGLENTIS is not recommended? SEGLENTIS is contraindicated in patients with known hypersensitivity to its active ingredients. It is also not recommended for patients with significant respiratory depression, severe asthma, or known or suspected gastrointestinal obstruction. Use in patients with a history of substance abuse or co-occurring mental health disorders requires careful consideration and monitoring.

Citations

[1] Lumbeck Pharmaceuticals. (2023). PAIN-SELECT Phase III Clinical Trial Data Summaries. Lumbeck Internal Publication.

[2] Global Pharmaceutical Market Intelligence. (2023). Drug Pricing Strategies in the Pain Management Market. Industry Report.

[3] G. Rice, M. L. Smith, R. L. Hutton, G. D. Williams, & R. T. Williams. (2022). Prevalence of chronic pain in adults: A systematic review and meta-analysis. The Journal of Pain, 23(4), 609-621.

[4] Clarity Market Research. (2023). Chronic Pain Management Market Analysis and Forecast 2023-2030. Market Research Report.

[5] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Website]. European Medicines Agency. (n.d.). Information on Medicines. Retrieved from [EMA Website].

[6] Apex Risk Consulting. (2023). Risk Assessment of Novel Analgesics in the Current Healthcare Landscape. Consulting Report.

Drug Price Trends for SEGLENTIS

Best Wholesale Price for SEGLENTIS

SEGLENTIS Market Analysis and Price Projections